Charles Schwab Investment Management Inc. Buys 16,258 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Charles Schwab Investment Management Inc. lifted its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 602,321 shares of the medical device company's stock after purchasing an additional 16,258 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.92% of Tandem Diabetes Care worth $21,696,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TNDM. Jones Financial Companies Lllp boosted its position in shares of Tandem Diabetes Care by 195.8% during the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock worth $41,000 after buying an additional 748 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of Tandem Diabetes Care by 163.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock worth $65,000 after buying an additional 1,101 shares during the period. US Bancorp DE boosted its position in shares of Tandem Diabetes Care by 15.2% during the fourth quarter. US Bancorp DE now owns 38,708 shares of the medical device company's stock worth $1,394,000 after buying an additional 5,108 shares during the period. GW&K Investment Management LLC boosted its position in shares of Tandem Diabetes Care by 18.0% during the fourth quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock worth $76,488,000 after buying an additional 323,674 shares during the period. Finally, Oppenheimer Asset Management Inc. boosted its position in shares of Tandem Diabetes Care by 4.4% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 61,704 shares of the medical device company's stock worth $2,223,000 after buying an additional 2,612 shares during the period.

Remove Ads

Analyst Upgrades and Downgrades

TNDM has been the subject of several recent research reports. Robert W. Baird reduced their price objective on Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating for the company in a research report on Thursday, February 27th. The Goldman Sachs Group reduced their price objective on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Citigroup cut Tandem Diabetes Care from a "buy" rating to a "neutral" rating and reduced their price target for the company from $35.00 to $24.00 in a research report on Tuesday, March 4th. Morgan Stanley cut Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $45.00 to $22.00 in a research report on Wednesday, March 5th. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $63.00 price target on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. Eight analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $45.38.

Tandem Diabetes Care Stock Performance

NASDAQ:TNDM traded down $0.36 on Friday, hitting $20.29. The company's stock had a trading volume of 1,365,105 shares, compared to its average volume of 1,467,349. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The stock has a fifty day moving average of $29.70 and a two-hundred day moving average of $33.86. The firm has a market capitalization of $1.35 billion, a P/E ratio of -10.51 and a beta of 1.45. Tandem Diabetes Care, Inc. has a one year low of $17.64 and a one year high of $53.69.

Insider Transactions at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos bought 10,538 shares of the stock in a transaction dated Friday, March 7th. The shares were bought at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the purchase, the chief operating officer now owns 10,538 shares in the company, valued at approximately $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.20% of the stock is owned by corporate insiders.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.